Mindpeak vs Visiopharm (2026)
These two overlap most directly, both CE marked immunohistochemistry scorers covering HER2, Ki-67, and PD-L1 with no FDA clearance, so the decision comes down to distribution philosophy and where the evidence sits. If you want algorithms that follow your laboratory across whatever workspace you run and rest on independent validation, start with Mindpeak. If your laboratory standardizes on Agilent assays and you want the broadest certified portfolio, start with Visiopharm. Mindpeak is platform portable, embedded in PathAI, and is the rare vendor here with genuinely independent third party evidence. Visiopharm is coupled to Agilent as its Diagnostic Package, holds the deepest run of IVDR clearances, and can point to a named, quantified deployment reporting real time and cost savings.
- Independent validation: third party studies, including work by Abele and colleagues and a concordance study at Aga Khan University Hospital, rather than only vendor run or single deployment evidence.
- Platform portable and assay neutral: embedded in PathAI's AISight and tied to no assay maker, so the algorithms follow the laboratory rather than a specific assay line.
- Cell level breast depth: BreastIHC distinguishes tumor from non tumor structures at the cellular level, in the highest volume biomarker workload.
- The deepest certified portfolio: the PD-L1 APP is its ninth IVDR clearance, and coverage extends beyond scoring to metastasis and invasive tumor detection across breast, lung, prostate, and colorectal cancer.
- A named, quantified deployment: at UMC Utrecht inside a Sectra system, reporting increased metastasis detection sensitivity, roughly 35 percent time saved, and reduced immunohistochemistry cost.
- Assay integrated for Agilent laboratories: validated to Agilent assays and the Omnis platform and sold as the Visiopharm Diagnostic Package.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Mindpeak and Visiopharm are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Mindpeak | Visiopharm |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2018 | 2001 |
| Headquarters | Hamburg, Germany | Hoersholm, Denmark |
| Website | mindpeak.ai | visiopharm.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Mindpeak its top capability grade on AI Centrality. Set against Visiopharm, Mindpeak does not grade higher on any scored axis, though the two are level on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Visiopharm its top capability grade on AI Centrality. Set against Mindpeak, Visiopharm grades higher on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose Mindpeak or Visiopharm?
The AI Health Index grades Visiopharm higher than Mindpeak on every axis that separates them, Model Supply Chain Disclosure and AI Liability and Recourse. Mindpeak does not grade higher on any scored axis.
Where do Mindpeak and Visiopharm differ most?
The widest separation the AI Health Index records between Mindpeak and Visiopharm is on Model Supply Chain Disclosure, where Mindpeak grades D and Visiopharm grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Mindpeak and Visiopharm grade the same?
The AI Health Index grades Mindpeak and Visiopharm the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Mindpeak and Visiopharm not disclosed?
At the last review, at least one of Mindpeak and Visiopharm published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Both are CE-IVD only with no FDA clearance, and neither publishes pricing, a security attestation, or demographic subgroup analysis, though Visiopharm's three site validation is a partial answer to generalization. Visiopharm's prostate APP carries the older IVDD mark through its DeepBio supplier rather than IVDR, and its coupling to Agilent is a benefit for Agilent shops and a constraint for others.
Mindpeak's clinical coverage is narrower than its product list implies, since its prostate and other assays are research use only, and because its algorithms run inside a third party platform, data residency and stewardship follow the host rather than Mindpeak. Both report concordance and efficiency evidence rather than patient outcomes.